SKB BIO-B (06990) has announced that its Investigational New Drug (IND) application for SKB103 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). SKB103 is a novel bispecific antibody-drug conjugate (bsADC) independently developed by the company, targeting both a tumor-associated antigen and an immune-oncology antigen (TAA–PD-L1), for the treatment of advanced solid tumors. This marks the company's first TAA-PD-L1 bsADC to enter the clinical stage and its second bsADC for oncology treatment to advance to clinical trials, following SKB571. As a leader in the ADC field, the company has established a solid competitive edge. Its independently developed TROP2-targeted ADC and HER2-targeted ADC have already received market approval and demonstrated significant clinical efficacy with differentiated advantages. Meanwhile, the company continues to expand its innovative pipeline, focusing on next-generation oncology treatments, including advanced therapies such as radiopharmaceutical drug conjugates (RDCs) and bsADCs, striving to drive breakthroughs and innovation in current cancer treatment paradigms.